Specifically, the use of GLP-1RAs as a metabolic pretreatment before IVF/ICSI is increasing, though much of this remains off-label exploration (192, 193)
July 15, 2024
Semaglutide, a highly efficacious metabolic drug, has consistently exhibited substantial neuroprotective effects across a diverse array of preclinical models, addressing the key pathological features of neurodegeneration, including neuroinflammation, metabolic dysfunction, and apoptosis (Tipa et al., 2024)
ROLE OF EXCIPIENTS IN ORAL FORMULATIONS Excipients play crucial roles in enhancing the stability and bioavailability of oral GLP-1 formulations
However, based on preclinical data and early human trial findings, glucagon receptor co-activation in the context of concurrent GLP-1R and GIPR agonism is hypothesised to: Increase energy expenditure, potentially by promoting thermogenesis Enhance hepatic fat oxidation, which may reduce liver fat content Contribute to appetite suppression through central nervous system pathways These GCGR-mediated mechanisms are largely derived from preclinical and indirect human data and require confirmation in larger trials